Q3 EPS Estimate for USANA Health Sciences Cut by Analyst

USANA Health Sciences, Inc. (NYSE:USNA) – Analysts at Sidoti Csr lowered their Q3 2026 EPS estimates for shares of USANA Health Sciences in a research note issued on Wednesday, February 11th. Sidoti Csr analyst A. Lebiedzinski now expects that the company will post earnings per share of $0.49 for the quarter, down from their previous estimate of $0.54. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q4 2026 earnings at $0.52 EPS, FY2026 earnings at $1.84 EPS, Q1 2027 earnings at $0.64 EPS, Q2 2027 earnings at $0.65 EPS and FY2027 earnings at $2.77 EPS.

USNA has been the topic of several other research reports. Zacks Research lowered USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, January 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Monday, December 29th. Two research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $36.00.

USANA Health Sciences Stock Down 0.0%

Shares of NYSE USNA opened at $20.95 on Monday. The company has a market capitalization of $382.97 million, a PE ratio of 23.81, a P/E/G ratio of 0.95 and a beta of 0.67. USANA Health Sciences has a twelve month low of $18.48 and a twelve month high of $38.32. The firm has a fifty day simple moving average of $20.68 and a 200 day simple moving average of $23.75.

Hedge Funds Weigh In On USANA Health Sciences

Several large investors have recently added to or reduced their stakes in the business. National Bank of Canada FI raised its stake in shares of USANA Health Sciences by 166.6% in the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after purchasing an additional 1,201 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in USANA Health Sciences by 382.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock worth $73,000 after acquiring an additional 1,901 shares during the last quarter. CWM LLC grew its stake in shares of USANA Health Sciences by 109.7% in the 2nd quarter. CWM LLC now owns 2,762 shares of the company’s stock worth $84,000 after acquiring an additional 1,445 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of USANA Health Sciences by 52.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock valued at $106,000 after purchasing an additional 1,327 shares during the last quarter. Finally, Parallel Advisors LLC boosted its holdings in USANA Health Sciences by 1,354.3% during the fourth quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock worth $76,000 after purchasing an additional 3,589 shares during the last quarter. Institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.